Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., Ltd.) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.

Hengrui has ranked on Pharma Exec’s annual list of the top 50 global pharmaceutical companies for seven consecutive years. According to the list of the world's top 25 pipeline-scale pharmaceutical companies released by Citeline, an internationally renowned consulting organization, Hengrui has remained on the list for four consecutive years, and it ranks second globally in the number of independently developed pipelines.

Pursuing innovation for health—Hengrui has always prioritized scientific and technological innovation as its primary development strategy, and has continued to increase its R&D investment. To date, Hengrui has invested more than RMB 48 billion in R&D, taking a lead in China's pharmaceutical industry. We have built 14 R&D centers across the world, including in China, Japan, the United States, Australia and Switzerland, with a global R&D team of over 5,600 professionals. Our R&D investment leads to fruitful innovation. We have commercialized 24 new molecular entity drugs and 4 other innovative drugs in China. Additionally, we have more than 100 independently developed innovative candidates in the pipeline and more than 400 clinical trials being conducted globally. Our approach ensures a virtuous cycle in which each batch of approved drugs is immediately followed by another in clinical trials and yet another in the pipeline. We have also independently established a series of world-leading technology platforms, including proteolysis-targeting chimeras (PROTACs), peptides, monoclonal antibodies, bispecific antibodies (BsAbs), multi-specific antibodies, antibody drug conjugates (ADCs), radioligand therapy and AI-driven drug discovery, etc. These platforms serve as a strong foundation for fostering innovation and driving our R&D efforts.

Bringing Chinese innovative drugs to the world—Globalization is our long-term development strategy. At present, our pharmaceutical products have entered more than 40 countries and regions, and we are actively accelerating our expansion into global markets, with a particular focus on emerging ones. The company places equal emphasis on independent R&D and open cooperation, strengthening international cooperation based on its endogenous development. Since 2018, we have secured 16 out-licensing deals for our innovative drugs, with the total transaction amount reaching more than US$27 billion. Additionally, we have launched more than 20 international clinical trials for our innovative products. Through our international partners, Hengrui has obtained more than 20 registration approvals in the EU, the US, and Japan, including injections, oral preparations and inhalation anesthetics, to benefit more patients around the world.

Hengrui will proceed with the mission of "promoting a healthier life for humankind through advancements in science" and adhere to its vision of "becoming a global biopharmaceutical group through innovation". We will continue to engage in the innovation and development of treatments for diverse diseases and strive to develop more innovative drugs to benefit patients globally.